Roth MKM Initiates Coverage On Globus Medical with Buy Rating, Announces Price Target of $75
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jason Wittes has initiated coverage on Globus Medical (NYSE:GMED) with a Buy rating and a price target of $75.
October 20, 2023 | 9:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Globus Medical has been initiated with a Buy rating by Roth MKM, with a price target of $75.
The initiation of coverage by Roth MKM with a Buy rating and a price target of $75 indicates a positive outlook for Globus Medical. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100